加载中
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
前收盘价
US$3.07
+US$0.02 · +0.66%
盘中时间采用ET。市场数据可能有所延迟。
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
日内区间
当前US$3.07
52周区间
当前US$3.07
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
94
深度低估
情绪
41
多空交织
风险
69
高风险
动量
18
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
日内区间
当前US$3.07
52周区间
当前US$3.07
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 752.8万 USD | 334.4万 USD | 7.3万 USD | — | — |
| 毛利 | 752.8万 USD | 334.4万 USD | 7.3万 USD | — | — |
| 研究与开发 | 997.5万 USD | 1045.7万 USD | 1191.6万 USD | 1705.6万 USD | 1958.3万 USD |
| 销售、一般及管理费用 | 648.6万 USD | 731.7万 USD | 1007.9万 USD | 806.4万 USD | 618万 USD |
| 营业费用 | 1676.2万 USD | 1807.6万 USD | 2227万 USD | 2526.4万 USD | 2583.4万 USD |
| 利息收入 | 29.9万 USD | 25.4万 USD | 15.4万 USD | 283.1万 USD | 203.9万 USD |
| 利息支出 | 87.6万 USD | 96.2万 USD | 89.7万 USD | 150.8万 USD | 91.5万 USD |
| 折旧和摊销 | 61.5万 USD | 60.7万 USD | 61.5万 USD | 57.1万 USD | 34.4万 USD |
| 营业利润 | −923.4万 USD | −1473.2万 USD | −2219.7万 USD | −2526.4万 USD | −2583.4万 USD |
| 净利润 | −770.7万 USD | −1056.7万 USD | −2212.5万 USD | −2316.9万 USD | −2453.2万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$11.67
上涨空间 280.13%评级样本有限，仅4项
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
